Requirement of mineralocorticoid in congenital adrenal hyperplasia due to 11 beta-hydroxylase deficiency

J Clin Endocrinol Metab. 1986 Jul;63(1):36-40. doi: 10.1210/jcem-63-1-36.

Abstract

Marginal salt loss occurs in patients with congenital adrenal hyperplasia due to 11 beta-hydroxylase (11-OHase) deficiency treated with dexamethasone and is accompanied by increased PRA. The present study was undertaken to evaluate the effect of the stimulated renin-angiotensin system on pituitary-adrenal suppression. Seven patients with 11-OHase deficiency were subjected to a series of treatments with dexamethasone, cortisol, and combined cortisol and 9 alpha-fluorohydrocortisone. The latter combination suppressed PRA and sodium excretion, and produced better control of the pituitary-adrenal axis, as measured by plasma ACTA and serum 11-deoxycortisol. We conclude that in children with 11-OHase deficiency, PRA needs to be monitored, and when it is elevated, mineralocorticoid replacement is indicated.

MeSH terms

  • Adolescent
  • Adrenal Hyperplasia, Congenital* / drug therapy*
  • Adrenal Hyperplasia, Congenital* / metabolism
  • Adrenocorticotropic Hormone / blood
  • Child
  • Child, Preschool
  • Cortodoxone / blood
  • Dexamethasone / therapeutic use
  • Drug Administration Schedule
  • Drug Therapy, Combination
  • Female
  • Fludrocortisone / therapeutic use
  • Humans
  • Hydrocortisone / analogs & derivatives
  • Hydrocortisone / therapeutic use
  • Male
  • Mineralocorticoids / deficiency
  • Mineralocorticoids / therapeutic use*
  • Renin-Angiotensin System / drug effects
  • Steroid Hydroxylases / deficiency*
  • Water-Electrolyte Balance / drug effects

Substances

  • Mineralocorticoids
  • hydrocortisone acetate
  • Dexamethasone
  • Adrenocorticotropic Hormone
  • Steroid Hydroxylases
  • Fludrocortisone
  • Cortodoxone
  • Hydrocortisone